131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma

Pediatric Blood and Cancer

Volumn 60, Issue 5, 2013, Pages 879-884

  French, Sarah ^a,b   Dubois, Steven G ^a,b   Horn, Biljana ^a,b   Granger, Meaghan ^c   Hawkins, Randall ^a   Pass, Amy ^d   Plummer, Ellen ^d   Matthay, Katherine ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Pediatric Cardiothoracic Surgery   (United States)

^d CHILDREN S MEDICAL CENTER   (United States)

Author keywords

BMT; Neuroblastoma; Pediatric oncology

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ACETYLCYSTEINE; ANTIBIOTIC AGENT; BUSULFAN; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; ISOTRETINOIN; MELPHALAN; MORPHINE; TEMOZOLOMIDE; URSODEOXYCHOLIC ACID; (3 IODOBENZYL)GUANIDINE; ANTINEOPLASTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANTIBIOTIC THERAPY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BONE DISEASE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENGRAFTMENT; FEMALE; GASTROINTESTINAL TOXICITY; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; HYPOTHYROIDISM; INDUCTION CHEMOTHERAPY; LIVER VENOOCCLUSIVE DISEASE; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEUROBLASTOMA; NEUTROPHIL; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SCHOOL CHILD; SEPSIS; THROMBOCYTE; TREATMENT RESPONSE; AUTOTRANSPLANTATION; MULTIMODALITY CANCER THERAPY; STEM CELL TRANSPLANTATION;

3-IODOBENZYLGUANIDINE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MELPHALAN; NEUROBLASTOMA; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

MLCS; MLOWN;

EID: 84875000890     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24351     Document Type: Article

References (32)

1. Castleberry RP. Neuroblastoma. Eur J Cancer 1997; 33: 1430-1437 discussion 1437-8.
2. DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999; 21: 181-189.
3. Matthay KK. Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma. Pediatr Transplant 1999; 3: 72-77.
4. Stram DO, Matthay KK, O'Leary M, et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: A report of two concurrent children's cancer group studies. J Clin Oncol 1996; 14: 2417-2426.
5. Kretschmar CS, Kletzel M, Murray K, et al. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: A pediatric oncology group study. J Clin Oncol 2004; 22: 4119-4126.
6. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165-1173.
7. Frappaz D, Michon J, Coze C, et al. LMCE3 treatment strategy: Results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol 2000; 18: 468-476.
8. Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European bone marrow transplantation solid tumor registry. J Clin Oncol 1998; 16: 953-965.
9. Yanik GA, Parisi MT, Naranjo A, et al. MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study. J Clin Oncol 2010; 28: 15s(suppl; abstr 9516).
10. Carlin S, Mairs RJ, McCluskey AG, et al. Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res 2003; 9: 3338-3344.
11. Treuner J, Feine U, Niethammer D, et al. Scintigraphic imaging of neuroblastoma with [131-I]iodobenzylguanidine. Lancet 1984; 1: 333-334.
12. Hutchinson RJ, Sisson JC, Miser JS, et al. Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma. J Nucl Biol Med 1991; 35: 237-240.
13. 131I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy. Prog Clin Biol Res 1991; 366: 439-445.
14. Klingebiel T, Berthold F, Treuner J, et al. Metaiodobenzylguanidine (MIBG) in treatment of 47 patients with neuroblastoma: Results of the German neuroblastoma trial. Med Pediatr Oncol 1991; 19: 84-88.
15. 131I]iodobenzylguanidine in the treatment of neuroblastoma: The genoa experience. Q J Nucl Med 1995; 39: 58-60.
16. 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998; 16: 229-236.
17. Matthay KK, Panina C, Huberty J, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001; 42: 1713-1721.
18. 131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med 1991; 35: 244-247.
19. Matthay KK, Tan JC, Villablanca JG, et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to neuroblastoma therapy consortium study. J Clin Oncol 2006; 24: 500-506.
20. Ladenstein R, Poetschger U, Luksch R, et al. Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial. ASCO Annual Meeting Proceedings. J Clin Oncol 2011; 29: 18s(suppl; abstr 2).
21. Veal GJ, Nguyen L, Paci A, et al. Busulfan pharmakokinetics following intravenous and oral dosing regimens in children receiving high dose myeloablative chemotherapy for high risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. Eur J Cancer 2012 [Epub ahead of print].
22. Miano M, Garaventa A, Pizzitola MR, et al. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant 2001; 27: 571-574.
23. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363: 1324-1334.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
25. Ady N, Zucker JM, Asselain B, et al. A new 123I-MIBG whole body scan scoring method-Application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995; 31A: 256-261.
26. Matthay KK, Edeline V, Lumbroso J, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 2003; 21: 2486-2491.
27. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477.
28. Matthay KK, Quach A, Huberty J, et al. Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: A new approaches to neuroblastoma therapy phase I study. J Clin Oncol 2009; 27: 1020-1025.
29. Ladenstein R, Potschger U, Hartman O, et al. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: Lessons from more than 4000 procedures. Bone Marrow Transplant 2008; 41(suppl 2): S118-S127.
30. Yanik GA, Weiss B, Maris J, et al. Phase II trial of meta-iodobenzylguanidine (MIBG) with intensive chemotherapy and autologous stem cell transplant for high risk neuroblastoma. A new approaches to neuroblastoma study. Adv Neuroblastoma Res 2010; Stockholm (Sweden). Abstr no. OR58.
31. Valteau-Couanet D, Benhamou E, Vassal G, et al. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 2000; 25: 937-942.
32. Diaz MA, Vicent MG, Madero L. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors. Bone Marrow Transplant 1999; 24: 1157-1159.